✨ Medicines Consent Notices
170
NEW ZEALAND GAZETTE
No. 8
Health
Medicines Act 1981
Consent to the Distribution of New Medicines
Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new medicines set out in the Schedule hereto:
Schedule
Product: Accuretic
Active Ingredient(s): Hydrochlorothiazide 12.5mg
Quinapril hydrochloride 10.832mg equivalent to 10mg quinapril free base
Dosage Form: Film coated tablet
New Zealand Sponsor: Pfizer Laboratories Limited
Manufacturer(s): Godecke AG, Freiburg, Germany
Product: Accuretic
Active Ingredient(s): Hydrochlorothiazide 12.5mg
Quinapril hydrochloride 21.664mg equivalent to 20mg quinapril free base
Dosage Form: Film coated tablet
New Zealand Sponsor: Pfizer Laboratories Limited
Manufacturer(s): Godecke AG, Freiburg, Germany
Product: Seretide
Active Ingredient(s): Fluticasone propionate 20mg equivalent to 125µg/dose
Salmeterol xinafoate 5.8mg equivalent to 25µg/dose salmeterol
Dosage Form: Aerosol inhaler, metered dose
New Zealand Sponsor: Glaxo Wellcome New Zealand Limited
Manufacturer(s): Glaxo Wellcome Operations, Speke, Liverpool, United Kingdom
Glaxo Wellcome Production, Evreux, France
Product: Seretide
Active Ingredient(s): Fluticasone propionate 40mg equivalent to 250µg/dose
Salmeterol xinafoate 5.8mg equivalent to 25µg/dose salmeterol
Dosage Form: Aerosol inhaler, metered dose
New Zealand Sponsor: Glaxo Wellcome New Zealand Limited
Manufacturer(s): Glaxo Wellcome Operations, Speke, Liverpool, United Kingdom
Glaxo Wellcome Production, Evreux, France
Product: Seretide
Active Ingredient(s): Fluticasone propionate 8mg equivalent to 50µg/dose
Salmeterol xinafoate 5.8mg equivalent to 25µg/dose salmeterol
Dosage Form: Aerosol inhaler, metered dose
New Zealand Sponsor: Glaxo Wellcome New Zealand Limited
Manufacturer(s): Glaxo Wellcome Operations, Speke, Liverpool, United Kingdom
Glaxo Wellcome Production, Evreux, France
Dated this 17th day of January 2001.
G. R. BOYD, Chief Advisor, Safety and Regulation (pursuant to delegation given by the Minister of Health on the 20th day of February 1997).
go529
Renewal of Provisional Consent to the Distribution of a New Medicine
Pursuant to section 23 of the Medicines Act 1981, the Minister of Health hereby provisionally consents to the sale, supply or use in New Zealand of the new medicine set out in the Schedule hereto:
Schedule
Product: Temodal
Active Ingredient(s): Temozolomide 100mg
Dosage Form: Capsule
New Zealand Sponsor: Schering-Plough Pty Limited
Manufacturer(s): Integrated Therapeutics Group Inc., Subsidiary Schering-Plough Corp., Iowa City, Iowa, United States of America
Next Page →
Online Sources for this page:
VUW Te Waharoa —
NZ Gazette 2001, No 8
Gazette.govt.nz —
NZ Gazette 2001, No 8
✨ LLM interpretation of page content
🏥 Consent to the Distribution of New Medicines
🏥 Health & Social Welfare17 January 2001
Medicines Act 1981, New Medicines, Distribution Consent, Pharmaceuticals
- G. R. Boyd, Chief Advisor, Safety and Regulation
🏥 Renewal of Provisional Consent to the Distribution of a New Medicine
🏥 Health & Social WelfareMedicines Act 1981, Provisional Consent, Temodal, Pharmaceuticals